CR20120558A - Terapia de combinación que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinético - Google Patents

Terapia de combinación que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinético

Info

Publication number
CR20120558A
CR20120558A CR20120558A CR20120558A CR20120558A CR 20120558 A CR20120558 A CR 20120558A CR 20120558 A CR20120558 A CR 20120558A CR 20120558 A CR20120558 A CR 20120558A CR 20120558 A CR20120558 A CR 20120558A
Authority
CR
Costa Rica
Prior art keywords
hiv
protease inhibitor
combination therapy
pharmacocinetic
potentiator
Prior art date
Application number
CR20120558A
Other languages
English (en)
Inventor
Randall Lee Tressler
Hernan Valdez
Original Assignee
Phivco 1 Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44227938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120558(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Phivco 1 Llc filed Critical Phivco 1 Llc
Publication of CR20120558A publication Critical patent/CR20120558A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención da a conocer una novedosa terapia de combinación para el tratamiento de VIH-1, que se apoya en una combinación de cuando menos un antagonista de CCR5, de cuando menos un inhibidor de proteasa de VIH-1, y de cuando menos un potenciador farmacocinético del cuando menos un antagonista de CCR5 y/o cuando menos un inhibidor de proteasa de VIH-1.
CR20120558A 2010-04-02 2012-11-01 Terapia de combinación que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinético CR20120558A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32042810P 2010-04-02 2010-04-02

Publications (1)

Publication Number Publication Date
CR20120558A true CR20120558A (es) 2013-04-09

Family

ID=44227938

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120558A CR20120558A (es) 2010-04-02 2012-11-01 Terapia de combinación que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinético

Country Status (20)

Country Link
US (1) US20130023496A1 (es)
EP (1) EP2552429A1 (es)
JP (1) JP2013523716A (es)
KR (1) KR20130025899A (es)
CN (1) CN102905698A (es)
AU (1) AU2011234013A1 (es)
BR (1) BR112012024522A2 (es)
CA (1) CA2794443A1 (es)
CL (1) CL2012002743A1 (es)
CO (1) CO6630124A2 (es)
CR (1) CR20120558A (es)
DO (1) DOP2012000253A (es)
EA (1) EA201290852A1 (es)
MA (1) MA34215B1 (es)
MX (1) MX2012011415A (es)
PE (1) PE20130529A1 (es)
PH (1) PH12012501930A1 (es)
SG (1) SG184176A1 (es)
WO (1) WO2011121558A1 (es)
ZA (1) ZA201207214B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206702B1 (en) 2001-08-08 2011-12-28 Tobira Therapeutics, Inc. Bicyclic compound, production and use thereof
SG10201708595YA (en) * 2013-05-15 2017-11-29 Tobira Therapeutics Inc Cenicriviroc compositions and methods of making and using the same
EP3777863A1 (en) * 2014-09-12 2021-02-17 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
US11292785B2 (en) 2018-02-02 2022-04-05 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof
WO2022223007A1 (zh) * 2021-04-23 2022-10-27 中国人民解放军军事科学院军事医学研究院 抗病毒多肽化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
AU729415B2 (en) 1996-07-12 2001-02-01 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP0916668A4 (en) 1996-07-29 2000-08-16 Banyu Pharma Co Ltd CHEMOKIN RECEPTOR ANTAGONISTS
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
AU5604998A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1998025605A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1999032468A1 (en) 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Anilide derivative, production and use thereof
AU762349B2 (en) * 1998-11-04 2003-06-26 Pharmacia & Upjohn Company Method for improving the pharmacokinetics of tipranavir
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
AR025884A1 (es) 1999-10-01 2002-12-18 Takeda Pharmaceutical Compuestos de amina ciclica, su produccion y su uso
CN100355753C (zh) 2000-05-26 2007-12-19 辉瑞大药厂 用于制备具有治疗作用的莨菪烷衍生物的中间体
EP2206702B1 (en) 2001-08-08 2011-12-28 Tobira Therapeutics, Inc. Bicyclic compound, production and use thereof
ES2274119T3 (es) * 2001-08-31 2007-05-16 Bristol-Myers Squibb Company Uso de atazavir en terapia.
PL372968A1 (en) 2002-04-08 2005-08-08 Pfizer Inc. Tropane derivatives as ccr5 modulators
KR100777885B1 (ko) 2003-10-03 2007-11-28 화이자 인코포레이티드 Ｈｉｖ 및 염증 치료를 위한 ｃｃｒ5 수용체 길항제 활성을갖는 이미다조피리딘 치환된 트로판 유도체
CA2616189C (en) * 2005-07-22 2019-03-26 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
CN101495145A (zh) * 2005-07-22 2009-07-29 原基因药物有限公司 用于减少受hiv-1感染的患者中病毒负荷的方法

Also Published As

Publication number Publication date
CO6630124A2 (es) 2013-03-01
DOP2012000253A (es) 2012-12-31
MA34215B1 (fr) 2013-05-02
CL2012002743A1 (es) 2012-12-14
EP2552429A1 (en) 2013-02-06
MX2012011415A (es) 2013-02-26
ZA201207214B (en) 2014-03-26
US20130023496A1 (en) 2013-01-24
KR20130025899A (ko) 2013-03-12
CA2794443A1 (en) 2011-10-06
SG184176A1 (en) 2012-10-30
EA201290852A1 (ru) 2013-04-30
PE20130529A1 (es) 2013-05-14
WO2011121558A1 (en) 2011-10-06
PH12012501930A1 (en) 2013-02-04
BR112012024522A2 (pt) 2017-08-08
CN102905698A (zh) 2013-01-30
JP2013523716A (ja) 2013-06-17
AU2011234013A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
MX393610B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres
CY1121379T1 (el) Πολυθεραπεια για την ισχαιμια
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
CL2018000198A1 (es) Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX338884B (es) Composiciones y metodos que comprenden variantes de proteasa.
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
CU24389B1 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
CL2013003145A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre.
CR20140232A (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
CY1112077T1 (el) Θεραπεια με πιρφενιδονη αποφευγοντας την φλουβοξαμινη
ECSP10010409A (es) INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
MX2016011938A (es) Composicion farmaceutica liquida.
BR112017028549A2 (pt) derivados de pirimidina como inibidores de btk e usos dos mesmos
CR20120558A (es) Terapia de combinación que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinético
MX2020005483A (es) Antagonistas de ildr2 y combinaciones de los mismos.
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
EA201071412A1 (ru) Дронедарон для предотвращения кардиоверсии
MX385003B (es) Compuestos para tratar el bloqueo de remielinizacion en enfermedades asociadas con la expresion de la proteina de envoltura herv-w.
ES2722323T3 (es) Composición fertilizante que incluye un inhibidor de la actividad de la ureasa
CL2012001758A1 (es) Uso de compuestos derivados de 8-hidroxiquinolin-7-carboxamida y sus sales, para el tratamiento y/o prevencion de infecciones fungicas.